BACKGROUND: We previously presented the safety and early efficacy of the inspIRE study (Study for Treatment of Paroxysmal Atrial Fibrillation [PAF] by Pulsed-field Ablation [PFA] System With Irreversible Electroporation [IRE]). With the study's conclusion, we report the outcomes of the full pivotal study cohort, with an additional analysis of predictors of success. METHODS: InspIRE was a prospective, multicenter, single-arm clinical trial of drug-refractory paroxysmal atrial fibrillation. Pulmonary vein isolation was performed with a variable-loop circular catheter integrated with a 3-dimensional mapping system. Follow-up with 24-hour Holter was at 3, 6, and 12 months, as well as remote rhythm monitoring: weekly from 3 to 5 months, monthly from 6 to 12 months, and for symptoms. The primary effectiveness end point (PEE) was acute pulmonary vein isolation plus freedom from any atrial arrhythmia at 12 months. Additional subanalyses report predictors of PEE success. RESULTS: The patient cohort included 186 patients: aged 59±10 years, female 30%, and CHA2DS2-VASc 1.3±1.2. The previously reported primary adverse event rate was 0%. One serious procedure-related adverse event, urinary retention, was reported. The PEE was achieved in 75.6% (95% CI, 69.5%-81.8%). The clinical success of freedom from symptomatic recurrence was 81.7% (95% CI, 76.1%-87.2%). Simulating a monitoring method used in standard real-world practice (without protocol-driven remote rhythm monitoring), this translates to a freedom from all and symptomatic recurrence of 85.8% (95% CI, 80.8%-90.9%) or 94.0% (95% CI, 90.6%-97.5%), respectively. Multivariate analyses revealed that left ventricular ejection fraction ≥60% (adjusted odds ratio, 0.30) and patients receiving ≥48 PFA applications (adjusted odds ratio, 0.28) were independent predictors of PEE success. Moreover, PEE success was 79.2% in patients who received ≥12 PFA applications per vein compared with 57.1% in patients receiving fewer PFA applications. CONCLUSIONS: The inspIRE study confirms the safety and effectiveness of pulmonary vein isolation using the novel 3-dimensional mapping integrated circular loop catheter. An optimal number of PFA applications (≥48 total or ≥12 per vein) resulted in an improved 1-year success rate of ≈80%. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04524364.

AZ Sint Jan Brugge Belgium

Centre for Cardiology and Angiology Department of Cardiovascular Diseases Vilnius University Lithuania

Department of Cardiology Na Homolce Hospital Prague Czech Republic

Helmsley Electrophysiology Center Mount Sinai Fuster Heart Hospital New York NY; Department of Cardiology Na Homolce Hospital Prague Czech Republic

IHU LIRYC ANR 10 IAHU 04 Centre Hospitalier Universitaire Bordeaux Bordeaux University Bordeaux France

Jessa Hospitals Hasselt Belgium

McGill University Health Center Montréal Canada

Medical University Graz Graz Austria

OLV Hospital Dienst Cardiologie Aalst Belgium

Ordensklinikum Linz GmbH Linz Austria

Ospedale Generale Regionale F Miulli UOC Cardiologia Bari Italy

University Hospital Center Split Split Croatia

University of Western Ontario London Canada

Ziekenhuis Oost Genk Belgium

Zobrazit více v PubMed

Reddy VY, Koruth J, Jais P, Petru J, Timko F, Skalsky I, Hebeler R, Labrousse L, Barandon L, Kralovec S, et al. . Ablation of atrial fibrillation with pulsed electric fields: an ultra-rapid, tissue-selective modality for cardiac ablation. JACC Clin Electrophysiol. 2018;4:987–995. doi: 10.1016/j.jacep.2018.04.005 PubMed

Verma A, Asivatham SJ, Deneke T, Castellvi Q, Neal RE, 2nd. Primer on pulsed electrical field ablation: understanding the benefits and limitations. Circ Arrhythm Electrophysiol. 2021;14:e010086. doi: 10.1161/CIRCEP.121.010086 PubMed

Yavin H, Brem E, Zilberman I, Shapira-Daniels A, Datta K, Govari A, Anic A, Wazni O, Anter E. Circular multielectrode pulsed-field ablation catheter Lasso pulsed field ablation: lesion characteristics, durability, and effect on neighboring structures. Circ Arrhythm Electrophysiol. 2021;14:e009229. doi: 10.1161/CIRCEP.120.009229 PubMed PMC

Reddy VY, Anter E, Rackauskas G, Peichl P, Koruth JS, Petru J, Funasako M, Minami K, Natale A, Jais P, et al. . Lattice-tip focal ablation catheter that toggles between radiofrequency and pulsed field energy to treat atrial fibrillation: a first-in-human trial. Circ Arrhythm Electrophysiol. 2020;13:e008718. doi: 10.1161/CIRCEP.120.008718 PubMed

Reddy VY, Dukkipati SR, Neuzil P, Anic A, Petru J, Funasako M, Cochet H, Minami K, Breskovic T, Sikiric I, et al. . Pulsed field ablation of paroxysmal atrial fibrillation: 1-year outcomes of IMPULSE, PEFCAT, and PEFCAT II. JACC Clin Electrophysiol. 2021;7:614–627. doi: 10.1016/j.jacep.2021.02.014 PubMed

Reddy VY, Neuzil P, Koruth JS, Petru J, Funosako M, Cochet H, Sediva L, Chovanec M, Dukkipati SR, Jais P. Pulsed field ablation for pulmonary vein isolation in atrial fibrillation. J Am Coll Cardiol. 2019;74:315–326. doi: 10.1016/j.jacc.2019.04.021 PubMed

Reddy VY, Peichl P, Anter E, Rackauskas G, Petru J, Funasako M, Minami K, Koruth JS, Natale A, Jais P, et al. . A focal ablation catheter toggling between radiofrequency and pulsed field energy to treat atrial fibrillation. JACC Clin Electrophysiol. 2023;9:1786–1801. doi: 10.1016/j.jacep.2023.04.002 PubMed

Turagam MK, Neuzil P, Schmidt B, Reichlin T, Neven K, Metzner A, Hansen J, Blaauw Y, Maury P, Arentz T, et al. . Safety and effectiveness of pulsed field ablation to treat atrial fibrillation: one-year outcomes from the MANIFEST-PF registry. Circulation. 2023;148:35–46. doi: 10.1161/CIRCULATIONAHA.123.064959 PubMed

Verma A, Haines DE, Boersma LV, Sood N, Natale A, Marchlinski FE, Calkins H, Sanders P, Packer DL, Kuck KH, et al. ; PULSED AF Investigators. Pulsed field ablation for the treatment of atrial fibrillation: PULSED AF pivotal trial. Circulation. 2023;147:1422–1432. doi: 10.1161/CIRCULATIONAHA.123.063988 PubMed PMC

Duytschaever M, De Potter T, Grimaldi M, Anic A, Vijgen J, Neuzil P, Van Herendael H, Verma A, Skanes A, Scherr D, et al. ; inspIRE Trial Investigators. Paroxysmal atrial fibrillation ablation using a novel variable-loop biphasic pulsed field ablation catheter integrated with a 3-dimensional mapping system: 1-year outcomes of the multicenter inspIRE study. Circ Arrhythm Electrophysiol. 2023;16:e011780. doi: 10.1161/CIRCEP.122.011780 PubMed PMC

Duytschaever M, Vijgen J, De Potter T, Scherr D, Van Herendael H, Knecht S, Kobza R, Berte B, Sandgaard N, Albenque JP, et al. . Standardized pulmonary vein isolation workflow to enclose veins with contiguous lesions: the multicentre VISTAX trial. Europace. 2020;22:1645–1652. doi: 10.1093/europace/euaa157 PubMed

Di Biase L, Monir G, Melby D, Tabereaux P, Natale A, Manyam H, Athill C, Delaughter C, Patel A, Gentlesk P, et al. ; SURPOINT Postapproval Trial Investigators. Composite index tagging for PVI in paroxysmal AF: a prospective, multicenter postapproval study. JACC Clin Electrophysiol. 2022;8:1077–1089. doi: 10.1016/j.jacep.2022.06.007 PubMed

Reddy VY, Gerstenfeld EP, Natale A, Whang W, Cuoco FA, Patel C, Mountantonakis SE, Gibson DN, Harding JD, Ellis CR, et al. ; ADVENT Investigators. Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation. N Engl J Med. 2023;389:1660–1671. doi: 10.1056/NEJMoa2307291 PubMed

Osorio J, Hussein AA, Delaughter MC, Monir G, Natale A, Dukkipati S, Oza S, Daoud E, Di Biase L, Mansour M, et al. ; Q-FFICIENCY Trial Investigators. Very high-power short-duration, temperature-controlled radiofrequency ablation in paroxysmal atrial fibrillation: the prospective multicenter Q-FFICIENCY trial. JACC Clin Electrophysiol. 2023;9:468–480. doi: 10.1016/j.jacep.2022.10.019 PubMed

Schmidt B, Bordignon S, Neven K, Reichlin T, Blaauw Y, Hansen J, Adelino R, Ouss A, Futing A, Roten L, et al. . EUropean real-world outcomes with Pulsed field ablatiOn in patients with symptomatic atRIAl fibrillation: lessons from the multi-centre EU-PORIA registry. Europace. 2023;25:euad185. doi: 10.1093/europace/euad185 PubMed PMC

Howard B, Verma A, Tzou WS, Mattison L, Kos B, Miklavcic D, Onal B, Stewart MT, Sigg DC. Effects of electrode-tissue proximity on cardiac lesion formation using pulsed field ablation. Circ Arrhythm Electrophysiol. 2022;15:e011110. doi: 10.1161/CIRCEP.122.011110 PubMed PMC

Hsu JC, Banker RS, Gibson DN, Gomez T, Berman D, Datta K, Chen Q, Doshi SK. Comprehensive dose-response study of pulsed field ablation using a circular catheter compared with radiofrequency ablation for pulmonary vein isolation: a preclinical study. Heart Rhythm O2. 2023;4:662–667. doi: 10.1016/j.hroo.2023.09.005 PubMed PMC

Yavin HD, Higuchi K, Sroubek J, Younis A, Zilberman I, Anter E. Pulsed-field ablation in ventricular myocardium using a focal catheter: the impact of application repetition on lesion dimensions. Circ Arrhythm Electrophysiol. 2021;14:e010375. doi: 10.1161/CIRCEP.121.010375 PubMed

Grimaldi M, Quadrini F, Caporusso N, Troisi F, Vitulano N, Delmonte V, Di Monaco A. Deep sedation protocol during atrial fibrillation ablation using a novel variable-loop biphasic pulsed field ablation catheter. Europace. 2023;25:euad222. doi: 10.1093/europace/euad222 PubMed PMC

Zobrazit více v PubMed

ClinicalTrials.gov
NCT04524364